Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis

Okamoto, Ken‐ichi; Saito, Yoshitaka; Yamaguchi, Atsushi; Takekuma, Yoh; Sugawara, Mitsuru

doi:10.1007/s10147-023-02385-z

Cited by 4 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combined use of nonsteroidal anti-inflammatory drugs (NSAIDs) (14,74), antibiotics (83), vitamin K antagonist fluindione (54, 74), RAASi (18,51) and diuretics (55,74) in cancer patients will increase the risk of ICI-AKI (21). In addition, acid inhibitors, including proton pump inhibitors (PPIs) (14,57,76) and histamine H2-receptor antagonists (H2RAs), reduce the therapeutic effect of ICIs and increase the risk of AKI (84). In the study by Chen et al, although the use of PPIs and NSAIDs were both risk factors for all-cause AKI and ICI-AKI, the odds ratio (OR) was higher for ICI-AKI than for all-cause AKI (1.77 vs. 2.42, 1.77 vs. 2.57, respectively) (85).…”

Section: Risk Factors For Development Of Ici-akimentioning

confidence: 99%

Immune checkpoint inhibitors and acute kidney injury

Zhou,

Gao,

Kong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

As a new type of anti-tumor immunotherapy, immune checkpoint inhibitors (ICIs) have improved the prognosis of multiple malignancies. However, renal complications are becoming more frequent. Nephrotoxicity often manifests as acute kidney injury (AKI), and the most common histopathological type is acute tubulointerstitial nephritis (ATIN). Based on previous studies of the incidence and potential risk factors for nephrotoxicity, in this review, we describe the mechanism of AKI after ICIs treatment, summarize the incidence, risk factors, and outcomes of AKI, and discuss the diagnosis and management of immune checkpoint inhibitors-associated acute kidney injury (ICI-AKI). In addition, we review the current status of ICIs rechallenge and the therapeutic strategies of ICIs applied in kidney transplant recipients. Finally, we emphasize the importance of collaboration between nephrologists and oncologists to guide the treatment of ICIs and the management of renal complications.

show abstract